FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/082981 [Registered on: 20/03/2025] Trial Registered Prospectively
Last Modified On: 15/08/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Ayurvedic treatment of hyperpiggmentation over face( Melasma) with Mukhakantikara Lepa and Manjishthadi Vati  
Scientific Title of Study   Evaluation of classical as well as present era causative factor of Vyanga w.s.r. to Melasma and its management by Manjishthadi Vati and Mukhakantikara Lepa  
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  shital uddhavrao sarang 
Designation  M.D. scholar 
Affiliation  Institute of teaching and research in ayurveda , jamnagar ,gujarat  
Address  Department of Rognidana 5th floor academic building ITRA Jamnagar,Gujarat.
Gurudwara road, opp. B Division police station, near reliance smart, valkeshwari,park colony, jamnagar, gujrat
Jamnagar
GUJARAT
361008
India 
Phone  7972248405  
Fax    
Email  shitalsarang2212@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Darshna Pandya 
Designation  Professor, HOD 
Affiliation  Institute of teaching and research in ayurveda , jamnagar ,gujarat  
Address  Department of Roganidana 5 th floor,academic building,ITRA Jamnagar,Gujrat
Gurudwara road, opp. B Division police station, near reliance smart, valkeshwari,park colony, jamnagar, gujrat
Jamnagar
GUJARAT
361008
India 
Phone  9099011095  
Fax    
Email  darshnapandya73@gmail.com  
 
Details of Contact Person
Public Query
 
Name  shital uddhavrao sarang 
Designation  M.D. scholar 
Affiliation  Institute of teaching and research in ayurveda , jamnagar ,gujarat  
Address  Department of Rognidana 5th floor academic building ITRA Jamnagar,Gujarat
Gurudwara road, opp. B Division police station, near reliance smart, valkeshwari,park colony, jamnagar, gujrat
Jamnagar
GUJARAT
361008
India 
Phone  7972248405  
Fax    
Email  shitalsarang2212@gmail.com  
 
Source of Monetary or Material Support  
Institute of teaching and research in ayurveda, Jamnagar,Gujarat  
 
Primary Sponsor  
Name  Institure of Teaching and Research in Ayurveda 
Address  Opp city B divison,near reliace smart ,gurudwara road Jamnagar,Gujarat,361008 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
shital sarang  Institute of Teaching and Research in Ayurveda  Opd no 13,Roga Nidan evam Vikriti Vigyan department,PG Hospital Jamnagar, Gujarat
Jamnagar
GUJARAT 
7972248405

shitalsarang2212@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC ITRA Jamnagar,gujrat  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:L989||Disorder of the skin and subcutaneous tissue, unspecified. Ayurveda Condition: VYANGAH, (2) ICD-10 Condition:L988||Other specified disorders of the skin and subcutaneous tissue. Ayurveda Condition: VYANGAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: Manjishthadi Vati, Reference: Acharya YT, Charaka Samhita of Agnivesa, Chakrapani Datta’s Ayurveda deepika (sans), 1st ed, Sutra, Shadvirechanashatasriteeyam, 4/10, Chaukhambha Publications, Varanasi, 2018, p-61, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/ Tablets, Dose: 2(g), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 2 Months, anupAna/sahapAna: Yes(details: -lukewarmwater), Additional Information: -
2Intervention ArmProcedure-lepa, लेप (Procedure Reference: Susrut samhita,by Kaviraj Ambikadutta Shastri,Edited with Ayurveda Tatva Sandipika Hindi commentary ,Sutrasthan Vranlepanbandhavidhi18/6 Chaukhambha Publications,New delhi p-97 , Procedure details: Patient will be advised to take Mukhakantikara Lepa in required quantity mix with water to form paste then to apply on affected area.The Lepa is to be applied in upward direction & very thin layer is to be made.Lepa is to apply during day time only and to be removed as soon as it gets dried. )
(1) Medicine Name: Mukhakantikara Lepa, Reference: Chakradatta of Chakrapanidatta, with the hindi commentary of vaidyapabha, Ramnath dvivedy editors, chaukhamba Sanskrit sansthan Varanasi reprint edition 2005 ,55/45 p-315 , Route: Topical, Dosage Form: Churna/ Powder, Dose: 7(g), Frequency: bd, Duration: 2 Months
3Comparator ArmProcedure-lepa, लेप (Procedure Reference: Susrut samhita,by Kaviraj Ambikadutta Shastri,Edited with Ayurveda Tatva Sandipika Hindi commentary ,Sutrasthan Vranlepanbandhavidhi18/6 Chaukhambha Publications,New delhi p-97, Procedure details: Patient will be advised to take Mukhakantikara Lepa in required quantity mix with water to form paste then to apply on affected area.The Lepa is to be applied in upward direction & very thin layer is to be made.Lepa is to apply during day time only & to be removed as soon as it gets dried. )
(1) Medicine Name: Mukhakantikara Lepa, Reference: Mukhakantikara Lepa, Reference: Chakradatta of Chakrapanidatta, with the hindi commentary of vaidyapabha, Ramnath dvivedy editors, chaukhamba Sanskrit sansthan Varanasi reprint edition 2005 ,55/45 p-315, Route: Topical, Dosage Form: Churna/ Powder, Dose: 7(g), Frequency: bd, Duration: 2 Months
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  55.00 Year(s)
Gender  Both 
Details  patients fulfilling the diagnostic criteria of Vyanga and patient willing to participate in the study  
 
ExclusionCriteria 
Details  patient age below 18 years and more than 55 years.Hyperpigmentation other than melasma like Acanthosis nigricans, niveous ota etc.Hyperpigmentation caused due to malignant melanoma, liver disease, congenital mark.Post inflammatory pigmentation or open wound on face.Patient suffering from contagious skin diseases, hereditary skin disorder.Pregnant or lactating women.Patient not willing to participate in the study.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Other 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Improvement MASI score and improvement MELASQOl
(Melasma Quality of Life scale) 
8 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
Improvement in Woods lamp examination  8 weeks 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "83"
Final Enrollment numbers achieved (India)="83" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/05/2025 
Date of Study Completion (India) 17/08/2026 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Completed 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

In this study, a total of 83 patients of Vyanga having age between 18-55 years and willing to participate were enrolled and surveyed to evaluate causative factor. Diagnosis was made on the basis of the presence of classical features of Vyanga, characterized by painless, thin, bluish-blackish discoloration of the facial skin. The depth of pigmentation was assessed by Wood’s lamp examination. Haematological, liver function as well as urine routine microscopic examination were carried out to rule out any underlying pathology.The majority of patients belonged to the 31–40 years age group (41%). Female patients constituted the majority (96%), with most participants being Hindu (95%) and married (90%). Among educational groups, HSC-qualified patients were predominant (36%), followed by graduates (32%). Most participants were housewives (86%). Regarding socio-economic status, the majority (65%) belonged to the middle class, while 77% were from urban areas. Among dietary factors, intake of Lavana Ahara (66%), Ruksha Ahara (65%), Snigdha-Ushna Ahara (63%), and Amla Ahara (60%), Tikshna Ahara (53%), Tikta Rasa (28%), Pishatanna (20%) were observed. Among the dietary habits, Vishamashana (51%) and Anashana/Alpashana (47%) were commonly observed, followed by Vidagdhajirna (33%) and Adhyashana (11%).Lifestyle-related factors like Atapa Sevana (72%), followed by Ratrijagarana (34%) and Ativyayama (28%) were observed.Psychological factors were predominantly Krodha (anger) (88%), followed by Chinta (stress) (86%) and Shoka (emotional grief) (20%) were observed. Risk-ratio analysis revealed a higher chance of the observed Nidanas with Vyanga.Among these, Anger (RR = 7.3) and Stress (RR = 6.5) showed the highest magnitude of association, followed by intake of Lavana Rasa (RR = 2.39), Ruksha Ahara (RR = 1.86), Snigdha-Ushna Ahara (RR = 1.67), Amla Ahara (RR = 1.51), Tikshna Ahara (RR= 1.12), and Vishamashana (RR = 1.02).Interventional study: Out of surveyed patients of Melasma 32 patients were randomly divided into two groups. Group A received Mukhakantikara Lepa and Manjishthadi Vati and Group B received Mukhakantikara Lepa alone. At the end of the study statistifically highly significant improvement was observed in both the group but on MASI score but percentage wise group A showed better improvement than group B. Further on woods lamp examination Group A showed 92.31% improvement in pigmentation Both groups showed a highly significant improvement in MASI score (p < 0.001), with 48.25% relief in Group A and 21.11% relief in Group B. On examination with Wood’s lamp, decreased pigmentation accentuation whereas in Group B it was 61.4% only with no change in type of melasma in either group.was observed in 92.31% of patients in Group A and 61.54% in Group B, with no change in the type of Melasma observed in either group.


 
Close